Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noae228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Anna Laemmerer und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Comprehensive Cancer Center and Comprehensive Center for Pediatrics, Medical University of Vienna, …. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Glioma, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Austrian Science Fund, German National Funding Organization.
Abstract (Originalsprache)
Background
Diffuse hemispheric glioma, H3 G34R/V-mutant (DHG-H3G34) is characterized by poor prognosis and lack of effective treatment options. DHG-H3G34R further harbor deactivation of alpha-thalassemia/mental retardation syndrome X-linked protein (ATRX; DHG-H3G34R_ATRX) suggesting a unique interaction of these 2 oncogenic alterations. In this study, we dissect their cell biological interplay, investigate the impact on telomere stabilization, and consequently validate a targeted therapy approach.
Methods
We characterized patient-derived primary pediatric high-grade glioma (pHGG) models for telomere-maintenance mechanisms, DNA damage stress (including protein expression, pH2AX/Rad51 foci, cell-cycle arrest) and their sensitivity towards poly-ADP ribose polymerase inhibitor (PARPi) combinations. Human induced pluripotent stem cells (iPSCs) were used for modeling the disease. The anticancer activity of PARPi combinations in vivo was studied in Chorioallantoic Membrane (CAM) and orthotopic in vivo experiments. Finally, we treated a DHG-H3G34R_ATRX patient with PARPi combination therapy.
Results
We elaborate that alternative lengthening of telomeres (ALT) is a key characteristic of DHG-H3G34R_ATRX. A dominant cooperative effect between H3G34R and ATRX loss in ALT activation also became apparent in iPSCs, which endogenously exert telomerase activity. In both, patient-derived DHG-H3G34R_ATRX models and H3G34R+/ATRX- iPSCs, the ALT-phenotype was associated with increased basal DNA damage stress, mediating synergistic susceptibility towards PARPi (talazoparib, niraparib) combinations with topoisomerase-I inhibitors (topotecan, irinotecan). In a first-of-its-kind case, treatment of a DHG-H3G34R_ATRX patient with the brain-penetrant PARP inhibitor niraparib and topotecan resulted in significant tumor reduction.
Conclusions
Our preclinical and clinical data strongly support the further development of PARPi together with DNA damage stress-inducing treatment regimens for DHG-H3G34R_ATRX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Comprehensive Cancer Center and Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Vienna BioCenter (VBC), PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria.
- IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna BioCenter (VBC), Vienna, Austria.
- Department of Neurosurgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Charles River Laboratories Germany GmbH, Freiburg, Germany.
ORCID-Profile: Christian Dorfer, Klaus Holzmann, Andreas Peyrl, Amedeo A Azizi, Christine Haberler, Walter Berger, Johannes Gojo
Förderung
- Austrian Science Fund
- German National Funding Organization
Zitieren
APA
Laemmerer, A., Lehmann, C., Mayr, L., Bruckner, K., Gabler, L., Senfter, D., Meyer, P., Balber, T., Pirker, C., Jaunecker, C. N., Kirchhofer, D., Vician, P., Griesser, M., Spiegl-Kreinecker, S., Schmook, M. T., Traub-Weidinger, T., Kuess, P., Eckert, F., Federico, A., …, & Gojo, J. (2025). Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae228
Vancouver
Laemmerer A, Lehmann C, Mayr L, Bruckner K, Gabler L, Senfter D, et al. Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae228
BibTeX
@article{Laemmerer2025,
author = {Laemmerer, Anna and Lehmann, Christian and Mayr, Lisa and Bruckner, Katharina and Gabler, Lisa and Senfter, Daniel and Meyer, Philipp and Balber, Theresa and Pirker, Christine and Jaunecker, Carola N and Kirchhofer, Dominik and Vician, Petra and Griesser, Michelle and Spiegl-Kreinecker, Sabine and Schmook, Maria T and Traub-Weidinger, Tatjana and Kuess, Peter and Eckert, Franziska and Federico, Aniello and Madlener, Sibylle and Stepien, Natalia and Robl, Bernhard and Baumgartner, Alicia and Hainfellner, Johannes A and Dieckmann, Karin and Dorfer, Christian and Roessler, Karl and Corsini, Nina S and Holzmann, Klaus and Schmidt, Wolfgang M and Peyrl, Andreas and Azizi, Amedeo A and Haberler, Christine and Beck, Alexander and Pfister, Stefan M and Schueler, Julia and Lötsch-Gojo, Daniela and Knoblich, Jürgen A and Berger, Walter and Gojo, Johannes},
title = {Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noae228}
}
EUVIMED